Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection-Reference-Cited by-同舟云学术

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

Published:2008-10-09 Issue:2 Volume:49 Page:358-363
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Mangia Alessandra,Minerva Nicola,Bacca Donato,Cozzolongo Raffaele,Agostinacchio Ernesto,Sogari Fernando,Scotto Gaetano,Vinelli Francesco,Ricci Giovanni Luciano,Romano Mario,Carretta Vito,Petruzzellis Daniela,Andriulli Angelo

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.22679/fullpdf

Reference23 articles.

1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial;Manns;Lancet,2001

2. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

3. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

4. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3;Mangia;N.Engl J Med,2005

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interaction of obesity and infections;Obesity Reviews;2015-09-10

2. The future of dual therapy for hepatitis C virus;Future Virology;2014-10

3. Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3;PLoS ONE;2014-09-19

4. A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: The TT4 randomized trial;Digestive and Liver Disease;2014-02

5. Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3;Current Hepatitis Reports;2013-10-09